Oxymorphone Drug Test Guide: Panels, Detection Windows & More
Evidence-based answer reviewed against SAMHSA cutoffs and FDA assay documentation · Updated September 2026
Quick answer: Semi-synthetic opioid agonist — not included on the federal 5-panel. Urine detects it roughly 1–3 days; hair archives ~90 days; saliva and blood track only recent use. Dedicated expanded urine assay ~100 ng/mL (oxymorphone/noroxymorphone) when ordered; otherwise only weak OXY-strip cross-reactivity.
Overview
This guide covers everything verifiable about how testing handles Oxymorphone (also searched as: opana, numorphan): which panels include it, detection windows across specimens, cutoff levels, false-positive risks, and legitimate prescription handling.
Panel membership
| Panel | Oxymorphone status |
|---|---|
| 5-Panel | ❌ Not included |
| 10-Panel | OXY strip cross-reactivity |
| 12-Panel | OXY strip cross-reactivity |
| DOT 5-panel (safety-sensitive) | ❌ Not included |
Detection windows
| Test type | Typical Oxymorphone detection window |
|---|---|
| Urine | occasional: 1–3 days · regular: up to 4 days |
| Saliva (Mouth Swab) | any: 1–2 days |
| Hair Follicles | up to 90 days |
| Blood | any: ~24 hours |
Cutoff levels
Dedicated expanded urine assay ~100 ng/mL (oxymorphone/noroxymorphone) when ordered; otherwise only weak OXY-strip cross-reactivity.
Cutoffs exist to separate real use from noise — dietary exposure, passive contact and legacy medications stay below them by design. Screen-above-cutoff results still require mass-spec confirmation before reporting.
Deep-dive facts
Oxymorphone is a semi-synthetic opioid that needs its own dedicated assay slot. Standard 5-panel opiate strips (morphine/codeine at 2,000 ng/mL) do not see it, and most 10/12-panel cups only catch it weakly through the oxycodone (OXY) strip's cross-reactivity.
Oxymorphone is also the active metabolite of oxycodone — every oxycodone user produces some oxymorphone. So an oxymorphone finding alone does not prove oxymorphone use; pain-management labs use ratios and confirmation to interpret it.
A valid prescription verifies as negative through the MRO process like any controlled opioid; keep the bottle or pharmacy record for the review call.
False positives & cross-reactivity
- No significant false positives documented on modern assays; oxymorphone is a normal metabolite of oxycodone, so the finding is not specific to oxymorphone use.
| Screen flagged | Documented cross-reactants (immunoassay tier only) |
|---|---|
| Amphetamines | Bupropion (bupropion), trazodone, phentermine, pseudoephedrine, labetalol, promethazine, methylphenidate |
| PCP | Dextromethorphan (dextromethorphan cough syrup), diphenhydramine (diphenhydramine), doxylamine (multi-symptom cold remedies), tramadol, venlafaxine (venlafaxine), ketamine |
| Opiates | Poppy seeds (true positive), quinine, dextromethorphan, ofloxacin/levofloxacin, rifampin |
| Benzodiazepines | Sertraline (sertraline), oxaprozin (case reports) |
| Methadone | Diphenhydramine, doxylamine, verapamil, quetiapine (quetiapine), clomipramine |
| Tricyclics (TCA) | Cyclobenzaprine (cyclobenzaprine), hydroxyzine, carbamazepine, diphenhydramine |
| Cannabinoids (THC) | Efavirenz, pantoprazole (isolated reports); dronabinol/dronabinol = true positive |
Legal status note
Schedule II by prescription.
Popular guides in this series
Certified labs nationwide · Results in 1–2 days
Need a test? Order online, test same-day →People also ask
How accurate are drug tests?
Lab-based immunoassay screens agree with confirmation testing ~97% of the time; confirmed GC–MS results are considered definitive. Home kits trade legal defensibility for convenience.
Do prescriptions count against me?
No — verified prescriptions report as negative through the Medical Review Officer. Declare medications at collection and answer the follow-up call.
Sources & further reading
- SAMHSA — Mandatory Guidelines for Federal Workplace Drug Testing Programs (cutoffs, MRO process)
- DOT — 49 CFR Part 40 procedures for transportation workplace testing
- Brahm NC et al., Mayo Clinic Proceedings 2008;83(1):66–76 — false-positive cross-reactivity reference
- FDA — drug-of-abuse test device labeling (detection window conventions)